Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
MWN-AI** Summary
Cosmos Health Inc. (NASDAQ: COSM) has made a significant strategic advancement by entering the U.S. market through an agreement with DolCas Biotech LLC, a New Jersey-based nutraceutical manufacturer. This partnership marks the beginning of U.S.-based production at GMP-certified facilities, enabling Cosmos to mitigate tariff risks and streamline its supply chain. The company aims to enhance production oversight and scalability, thereby solidifying its position in the premium nutraceutical industry.
DolCas Biotech is known for developing clinically backed nutraceutical ingredients such as Curcugen® and Ginfort®. Their capability of vertically integrated manufacturing complements Cosmos Health’s mission of expanding its portfolio with scientifically validated products. The collaboration is anticipated to foster the development of innovative offerings that align with both companies' visions for growth.
Greg Siokas, CEO of Cosmos Health, expressed pride in this essential milestone, emphasizing that the U.S. manufacturing launch strengthens their operational framework and reduces exposure to the complexities of international trade dynamics. Similarly, K. Gnaneshwar Rao of DolCas highlighted the alignment of their strategic goals and mutual commitment to quality.
Cosmos Health, established in 2009, operates as a diversified healthcare entity with a focus on innovative R&D, proprietary brands, and telehealth services. The company not only manufactures a range of healthcare products within Europe through its subsidiary, Cana Laboratories, but is also venturing into global distribution through its expanding operations across North America and other regions.
Overall, this partnership represents a significant step for Cosmos Health, positioning it to compete effectively within the U.S. market while leveraging DolCas’s expertise in nutraceuticals. This move is crucial in navigating the complex landscape of global healthcare and product distribution.
MWN-AI** Analysis
Cosmos Health Inc. (NASDAQ:COSM) has made a significant move by entering the U.S. market with a strategic manufacturing partnership with DolCas Biotech. This development is noteworthy not only for its potential market implications but also for its robust risk mitigation strategies in today's volatile economic landscape.
By establishing U.S.-based manufacturing, Cosmos Health positions itself to sidestep the increasingly burdensome tariffs and logistical complexities that often accompany cross-border operations. The partnership with DolCas, a respected name in clinically validated nutraceuticals, leverages both companies' strengths—Cosmos’s diverse healthcare portfolio and DolCas's expertise in high-quality nutraceutical ingredients. This alignment will likely enhance Cosmos’s ability to produce scientifically-backed products that resonate with health-savvy consumers.
From an investor perspective, the commencement of production in GMP-certified facilities suggests a commitment to quality and regulatory compliance. This could bolster Cosmos Health’s image in a competitive market, especially as consumer trends continue to favor transparency and efficacy in health products. As the company aims to expand its footprint in the premium nutraceuticals segment, it is positioned well to capture a growing market share amid increasing demand for health-oriented products.
Additionally, this strategic expansion may lead to improved financial performance in the near-term due to reduced operational risks and cost efficiencies from domestic production. Investors should closely monitor how quickly Cosmos can scale its operations and how effectively it navigates the U.S. healthcare landscape.
In conclusion, Cosmos Health's entry into the U.S. market, coupled with its local manufacturing capabilities, presents a potentially lucrative opportunity. Investors should consider the stock's long-term growth potential driven by this strategic initiative, while remaining vigilant of the inherent risks in the healthcare sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC (“DolCas”), a New Jersey-based developer and manufacturer of clinically studied nutraceutical ingredients.
Cosmos Health is set to commence production in the United States at GMP-certified (Good Manufacturing Practice) facilities, marking a significant milestone in the Company’s operational expansion. This move not only mitigates tariff exposure and cross-border logistical risks but also enhances production control beyond its existing European footprint, positioning Cosmos to scale efficiently in the global healthcare market.
The agreement strengthens Cosmos Health’s position in the premium nutraceuticals space and supports its broader strategy to expand its portfolio with scientifically backed, high-efficacy ingredients, while also leveraging DolCas’s expertise in clinically validated formulations and vertically integrated manufacturing.
K. Gnaneshwar Rao, CEO at DolCas Biotech, commented: “We are thrilled to partner with Cosmos and are eager to build on this collaboration with a wide range of innovative products that will benefit both companies. Cosmos, under the visionary leadership of CEO Greg Siokas, has built an impressive portfolio of brands and products. His forward-thinking approach aligns perfectly with our values and ambitions. We see this as the beginning of a strong, strategic partnership and look forward to supporting Cosmos’ continued growth in the United States and globally.”
Greg Siokas, CEO of Cosmos Health, stated: “We are proud to reach this important milestone as we commence production in the United States through our agreement with DolCas Biotech, a partner widely recognized for its commitment to quality and innovation. This strategic move strengthens our supply chain, enhances production oversight, and positions Cosmos for scalable global growth. It also reduces exposure to tariff-related risks, adding resilience amid shifting trade dynamics.”
About DolCas Biotech LLC
DolCas Biotech LLC is a U.S.-based developer and marketer of branded, science-backed nutraceutical ingredients, founded in 2007 as an extension of Orcas Naturals founded in 1993. Its portfolio includes, among others, clinically supported products such as Curcugen® (turmeric), Ginfort® (ginger), Morikol® (marine collagen), and TruOliv® (olive polyphenols). Through its dedicated manufacturing arm in India, the company maintains full vertical integration and strict control over ingredient quality. Its facilities are GMP-certified, FDA-registered, and UL-audited, underscoring a strong commitment to regulatory excellence and product integrity.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( www.sec.gov ). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
Disclaimer
This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a COSM financial position. COSM financial position and all other information regarding the featured Company should be verified directly with COSM. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in COSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of COSM shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Compensation: Market Wire News and its affiliates has received six thousand dollars for Market Wire News advertising services from Relqo Media LLC for Brand Awareness Distribution, Corporate Communications, News, Press Release Enhancement and Social Media Solutions starting 2026-05-31 and ending 2026-06-05 provided by Market Wire News. To date, we have received a total of six thousand dollars. Please read our full disclaimer for compensation and more detailed information.
FAQ**
How does Cosmos Health Inc. (COSM) plan to leverage its U.S. manufacturing capabilities through the partnership with DolCas Biotech to enhance its product offerings in the premium nutraceuticals market?
What specific strategies is Cosmos Health Inc. (COSM) implementing to mitigate logistical risks and tariff exposure as it expands its operations in the U.S. market through U.S.-based manufacturing?
Can you elaborate on the anticipated impact of this strategic partnership between Cosmos Health Inc. (COSM) and DolCas Biotech on the overall growth trajectory of the company in the global healthcare sector?
In light of potential uncertainties such as international trade dynamics and market competition, how does Cosmos Health Inc. (COSM) plan to ensure the successful commercialization of its newly developed nutraceutical products?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Health Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
6.07% G/L:
$0.2657 Last:
2,370,160 Volume:
$0.2525 Open:
